The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

Next-Gen Therapies Drive Development Technologies

Miniaturized high-throughput screening is applicable to bispecific antibody development.

Picodroplet Technology Applications in Cell Line Development

Topic

Articles

The first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy receives accelerated approval by FDA. 

FDA Grants Accelerated Approval for Recurrent or Metastatic Cervical Cancer Treatment to Tivdak

In an amendment to their existing contract manufacturing agreement, Celsian and Poly Pharm expand GEN-1 program collaboration to add clinical and commercial batches of investigational vaccine.

Celsion and Poly Pharm to Manufacture Celsion’s DNA-Based Vaccine

The research collaboration between AstraZeneca and VaxEquity aims to discover and develop self-amplifying RNA therapeutics.

AstraZeneca Enters into Research Collaboration With VaxEquity

Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.

Celularity and Oncternal Therapeutics to Research Placental-Derived Cellular Therapies

Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.

Novartis Acquires Arctos Medical, Expanding Optogenetics Profile

UCR scientists are researching whether a plant-based messenger RNA vaccine can be created and aim to eliminate the need for the refrigeration of mRNA vaccines during transport and storage.

Researchers from the University of California Riverside Investigate Plant-Based mRNA Vaccines

Boehringer Ingelheim and Twist Bioscience will use Twist’s antibody libraries to discover therapeutic antibody candidates.

Boehringer Ingelheim and Twist Bioscience Team Up for Therapeutic Antibody Discovery

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

Moderna and ILCM Announce Collaboration to Develop mRNA Therapeutic for CN-1

Kevin Noonan is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s biotechnology and pharmaceuticals practice group. 

Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.

NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulations

Joana S. Cristóvão, PhD, jscristovao@hovione.com, is an analytical scientist at Hovione Farmaciência S.A., R&D, Analytical Development.

Salomé Neto was a Master’s student at Hovione Farmaciência S.A., R&D, Analytical Development.

Establishing analytical workflows for complex biopharmaceutical molecules can help predict their risk of degradation.